Published in J Clin Invest on August 01, 1994
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol (2011) 2.43
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol (2009) 2.13
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev (2010) 1.95
Mutational analysis of the human nucleotide excision repair gene ERCC1. Nucleic Acids Res (1996) 1.53
ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer (2005) 1.49
Apoptosis and molecular targeting therapy in cancer. Biomed Res Int (2014) 1.47
Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun (2010) 1.37
Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer (2013) 1.27
Cancer cell adaptation to chemotherapy. BMC Cancer (2005) 1.21
C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency. Genome Res (2014) 1.21
Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer (2010) 1.19
Bim protein degradation contributes to cisplatin resistance. J Biol Chem (2011) 1.13
ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer (2008) 1.11
Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J (2011) 1.09
Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem (2014) 1.09
Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol (2013) 1.01
Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther (2011) 0.96
KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. PLoS One (2012) 0.95
β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol (2013) 0.94
Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment. Int J Surg Oncol (2012) 0.93
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer (2014) 0.91
High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J Transl Med (2011) 0.91
ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol (2008) 0.88
Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. Chembiochem (2011) 0.88
Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Arch (2011) 0.86
Resistance to platinum-based chemotherapy in lung cancer cell lines. Cancer Chemother Pharmacol (2010) 0.86
Association studies of excision repair cross-complementation group 1 (ERCC1) haplotypes with lung and head and neck cancer risk in a Caucasian population. Cancer Epidemiol (2010) 0.86
Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology (1998) 0.86
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol Oncol (2012) 0.86
Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines. Mol Cell Proteomics (2014) 0.85
Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin. Cell Death Dis (2014) 0.85
Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. Biomark Insights (2008) 0.85
Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. Genomics Proteomics Bioinformatics (2014) 0.85
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer (2014) 0.84
Mechanisms of resistance to alkylating agents. Cytotechnology (1998) 0.84
ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine. Contemp Oncol (Pozn) (2015) 0.84
Involvement of the Ras/extracellular signal-regulated kinase signalling pathway in the regulation of ERCC-1 mRNA levels by insulin. Biochem J (1998) 0.83
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol (2016) 0.82
Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. Oncologist (2011) 0.82
Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res (2013) 0.82
Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC). J Ovarian Res (2011) 0.81
Predictive and prognostic markers in colorectal cancer. Gastrointest Cancer Res (2007) 0.81
Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer. Transl Oncol (2013) 0.81
Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells. J Exp Clin Cancer Res (2010) 0.80
Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody. Sci Rep (2014) 0.80
Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy. Int J Clin Exp Med (2015) 0.78
Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer. Int J Mol Sci (2014) 0.78
Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Sci Rep (2014) 0.78
DNA Repair Pathway Alterations in Bladder Cancer. Cancers (Basel) (2017) 0.77
The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. J Gynecol Oncol (2015) 0.77
Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneity. Mol Cell Oncol (2015) 0.77
The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer. Curr Genomics (2008) 0.77
Preincision complex-I from the excision nuclease reaction among cochlear spiral limbus and outer hair cells. J Mol Histol (2008) 0.76
Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Rev Anticancer Ther (2012) 0.76
Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer. Exp Ther Med (2010) 0.75
High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer. Oncol Lett (2016) 0.75
MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Sci Rep (2017) 0.75
Prognostic biomarkers in ovarian cancer. Cancer Biomark (2011) 0.75
Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget (2017) 0.75
Expression of Drug-Resistant Factor Genes in Hepatocellular Carcinoma Patients Undergoing Chemotherapy with Platinum Complex by Arterial Infusion. Pharmaceutics (2010) 0.75
Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity? Chin J Cancer Res (2017) 0.75
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem (2016) 0.75
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Invest New Drugs (2001) 0.75
Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells. J Biol Chem (1979) 6.31
Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci U S A (1985) 4.80
Proliferating cell nuclear antigen is required for DNA excision repair. Cell (1992) 4.65
Molecular cloning of a human DNA repair gene. Nature (1984) 3.50
Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain. Nature (1990) 3.23
Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell (1986) 3.17
Yeast DNA repair and recombination proteins Rad1 and Rad10 constitute a single-stranded-DNA endonuclease. Nature (1993) 2.60
T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet (1984) 2.28
Yeast RAD14 and human xeroderma pigmentosum group A DNA-repair genes encode homologous proteins. Nature (1992) 1.95
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol (1992) 1.74
Molecular genetics of eukaryotic DNA excision repair. Cancer Cells (1990) 1.65
Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest (1991) 1.62
ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst (1992) 1.46
Nucleotide-excision repair of DNA in cell-free extracts of the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1993) 1.44
Mutational analysis of the structure and function of the xeroderma pigmentosum group A complementing protein. Identification of essential domains for nuclear localization and DNA excision repair. J Biol Chem (1992) 1.38
Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res (1988) 1.23
Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis (1993) 1.18
DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA. Biochemistry (1989) 1.18
Identification of splicing mutations of the last nucleotides of exons, a nonsense mutation, and a missense mutation of the XPAC gene as causes of group A xeroderma pigmentosum. Mutat Res (1992) 1.09
Complementation of the xeroderma pigmentosum DNA repair synthesis defect with Escherichia coli UvrABC proteins in a cell-free system. Nucleic Acids Res (1990) 1.08
Induction of a mutant phenotype in human repair proficient cells after overexpression of a mutated human DNA repair gene. Nucleic Acids Res (1991) 1.02
Do we know the cause of xeroderma pigmentosum? Carcinogenesis (1990) 1.00
DNA cross-linked by cisplatin: a new probe for the DNA repair defect in xeroderma pigmentosum. Mol Biol Med (1987) 1.00
Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst (1991) 0.99
How relevant is the Escherichia coli UvrABC model for excision repair in eukaryotes? J Cell Sci (1991) 0.97
Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T cell lines. Mutat Res (1992) 0.88
Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutat Res (1993) 0.86
Host-cell reactivation of cis-diamminedichloroplatinum(II)-treated SV40 DNA in normal human, Fanconi anaemia and xeroderma pigmentosum fibroblasts. Mutat Res (1985) 0.86
High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. J Clin Oncol (1993) 0.85
High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancer. J Natl Cancer Inst (1988) 0.80
Xeroderma pigmentosum. A gene for tumour prevention. Nature (1990) 0.80
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol (1996) 2.67
Human microphthalmia associated with mutations in the retinal homeobox gene CHX10. Nat Genet (2000) 2.13
Isolation and characterization of the cDNA encoding human DNA methyltransferase. Nucleic Acids Res (1992) 2.10
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
Applications of free living plant growth-promoting rhizobacteria. Antonie Van Leeuwenhoek (2004) 1.99
Family-environment risk factors for attention-deficit hyperactivity disorder. A test of Rutter's indicators of adversity. Arch Gen Psychiatry (1995) 1.97
Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol (1996) 1.95
The impact of disease severity on the informed consent process in clinical research. Am J Med (1996) 1.94
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res (1996) 1.82
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol (1992) 1.74
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A (1987) 1.71
Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest (1991) 1.62
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med (1995) 1.60
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
A vaccine against coccidioidomycosis is justified and attainable. Med Mycol (2004) 1.48
Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res (1995) 1.46
ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst (1992) 1.46
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc (1999) 1.46
Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol (2000) 1.44
Acute leukemia following cisplatin-based chemotherapy in a patient with ovarian cancer. J Natl Cancer Inst (1990) 1.41
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol (1992) 1.39
Carrier-Borne Typhoid Fever in New York State: With Special Reference to Attack Rates Among Household Contacts. Am J Public Health Nations Health (1937) 1.38
Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci (2005) 1.37
Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest (1986) 1.35
Characterization of the role of IL-6 in the progression of prostate cancer. Prostate (1999) 1.33
Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem (1991) 1.32
Contribution of direct and indirect recognition pathways to T cell alloreactivity. J Exp Med (1993) 1.31
Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol (1993) 1.30
The role of anti-HLA antibodies in heart transplantation. Transplantation (1991) 1.27
Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci (2005) 1.24
Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res (2000) 1.23
A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res (1997) 1.20
Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis (1993) 1.18
Patient-health care provider communication during chemotherapy treatment: the perspectives of women with breast cancer. Patient Educ Couns (2001) 1.17
A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr (1993) 1.17
High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: a pilot study. Am J Psychiatry (1995) 1.16
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res (1993) 1.15
Methods for extracting and amplifying genomic DNA isolated from frozen serum. Nat Biotechnol (1998) 1.11
Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant (1997) 1.10
Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol (1992) 1.09
In vitro propagation and production of hepatitis E virus from in vivo-infected primary macaque hepatocytes. Virology (1996) 1.09
A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer (1998) 1.09
Allopurinol kinetics. Clin Pharmacol Ther (1978) 1.09
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (1991) 1.08
Routine sampling of air for fungi does not predict risk of invasive aspergillosis in immunocompromised patients. J Hosp Infect (2008) 1.08
Definition of an HLA-DPw2-restricted epitope on NS3, recognized by a dengue virus serotype-cross-reactive human CD4+ CD8- cytotoxic T-cell clone. J Virol (1993) 1.08
Cloning of the psbK gene from Synechocystis sp. PCC 6803 and characterization of photosystem II in mutants lacking PSII-K. J Biol Chem (1991) 1.05
A survey of respiratory disease among New York City postal and transit workers. 2. Ventilatory function test results. Environ Res (1969) 1.05
RGS3 inhibits G protein-mediated signaling via translocation to the membrane and binding to Galpha11. Mol Cell Biol (1999) 1.05
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer (1994) 1.03
Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures. J Immunol (1983) 1.03
Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene (2012) 1.03
Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res (1992) 1.03
A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol (2000) 1.03
Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol (1995) 1.02
Cloning and expression of the gene which encodes a tube precipitin antigen and wall-associated beta-glucosidase of Coccidioides immitis. Infect Immun (2001) 1.01
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol (2001) 1.00
Status of the eradication of indigenous wild poliomyelitis in the People's Republic of China. J Infect Dis (1997) 1.00
Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients. Transplantation (1991) 1.00
Recombinant urease and urease DNA of Coccidioides immitis elicit an immunoprotective response against coccidioidomycosis in mice. Infect Immun (2001) 1.00
Anti-idiotypic antibodies to anti-HLA receptors induced by pregnancy. Proc Natl Acad Sci U S A (1983) 1.00
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori (1998) 0.99
Descriptive study to compare patient recall of information: nurse-taught versus video supplement. Can Oncol Nurs J (1999) 0.98
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res (1999) 0.98
Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant (2004) 0.98
Activating transcription factor 3 induction in sympathetic neurons after axotomy: response to decreased neurotrophin availability. Neuroscience (2007) 0.97
Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem (1998) 0.97
Factors affecting self-efficacy and pain intensity in patients with chronic musculoskeletal pain seen in a specialist rheumatology pain clinic. Rheumatology (Oxford) (2008) 0.96
Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate (2000) 0.96
Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy. Environ Health Perspect (1993) 0.96
Malignant ascites as only manifestation of metastatic prostate cancer. Prostate Cancer Prostatic Dis (1999) 0.95
Volumetric bone mineral density--a potential role in paediatrics. Acta Paediatr Suppl (1995) 0.95
Oxygen-evolving photosystem II preparation from wild type and photosystem II mutants of Synechocystis sp. PCC 6803. Biochemistry (1992) 0.95
Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)--DNA adducts in cancer patients and animal models. Environ Health Perspect (1985) 0.94
Effect of antiidiotypic antibodies to HLA on graft survival in renal-allograft recipients. N Engl J Med (1987) 0.94
Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve (2001) 0.94
Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol Biomarkers Prev (1993) 0.93
The hsp60 gene of the human pathogenic fungus Coccidioides immitis encodes a T-cell reactive protein. Gene (1997) 0.93
Sequence, expression and functional analysis of the Coccidioides immitis ODC (ornithine decarboxylase) gene. Gene (2000) 0.93
Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia. Eur J Surg Oncol (2008) 0.93
Intracellular lipid accumulation inhibitory effect of Weissella koreensis OK1-6 isolated from Kimchi on differentiating adipocyte. J Appl Microbiol (2012) 0.92
Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr (1993) 0.92
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol (1996) 0.91
Immunological monitoring of heart allograft recipients. Transplant Proc (1987) 0.91
Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther (1999) 0.90
Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors. Biochem Pharmacol (2000) 0.90
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol (1999) 0.89
Impact of adversity on functioning and comorbidity in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (1995) 0.89
Elongation of alternating alpha 2,8/2,9 polysialic acid by the Escherichia coli K92 polysialyltransferase. Glycobiology (2001) 0.89
Proposal for new best estimates of the soil-to-plant transfer factor of U, Th, Ra, Pb and Po. J Environ Radioact (2008) 0.88